Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.6302
-0.0052-0.82%
Post-market: 0.63020.00000.00%16:02 EDT
Volume:1.10M
Turnover:673.51K
Market Cap:75.60M
PE:-0.44
High:0.6362
Open:0.6048
Low:0.5700
Close:0.6354
Loading ...

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine

Zacks
·
25 Feb

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
25 Feb

Top Midday Decliners

MT Newswires Live
·
25 Feb

Sector Update: Health Care Stocks Gain Monday Afternoon

MT Newswires Live
·
25 Feb

Invivyd Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

BUZZ-U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities

Reuters
·
24 Feb

Invivyd news ‘disappointing’ but not in model, says H.C. Wainwright

TIPRANKS
·
24 Feb

Invivyd's FDA Setback Highlight's Risks of Pipeline Concentration -- Market Talk

Dow Jones
·
24 Feb

5 Stocks That More Than Doubled Halfway Through Q1

Zacks
·
24 Feb

Invivyd Shares Fall 25% After FDA Declines to Expand Emergency Use Authorization of Co's Covid-19 Drug

THOMSON REUTERS
·
24 Feb

BUZZ-U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop

Reuters
·
24 Feb

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires Live
·
24 Feb

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Feb

Invivyd Shares Down as Regulators Decline Expanded Use for Covid-19 Treatment

Dow Jones
·
24 Feb

Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA

MT Newswires Live
·
24 Feb

BUZZ-Invivyd falls after US FDA declines to expand emergency use of COVID-19 drug

Reuters
·
24 Feb

Invivyd Shares Down 31.1% Premarket After FDA Declines to Expand Emergency Use Authorization of Co's Covid-19 Drug

THOMSON REUTERS
·
24 Feb

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of Pemgarda™ (Pemivibart) to Include Treatment of Mild-to-Moderate Covid-19 for Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing Pemgarda Eua for Pre-Exposure Prophylaxis of Covid-19 in Certain Immunocompromised Patients

THOMSON REUTERS
·
24 Feb

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

GlobeNewswire
·
24 Feb

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Insider Monkey
·
18 Feb